After considering the efficacy and safety of TREMFYA^® for your commercially insured adult patients with active psoriatic arthritis (PsA)

CHOOSE TREMFYA^®,
GET TREMFYA^®

First-line coverage of TREMFYA^® is available for nearly 75% of commercial patients¹*^†

*Within 5% of the access being stated.
^†Based on national commercial coverage across all lines of therapy. Collected in June 2021. Subject to change. Please see additional information and limitations below.

When you choose TREMFYA^®, different patient-support programs may help patients get TREMFYA^®, depending on their coverage. Patients with government insurance may not have coverage for TREMFYA^®.

Learn more about specific patient-support programs and eligibility requirements.

Collected in 06/21 and subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.

This may not represent 100% of formulary lives due to data limitations.

Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of June 2021.

START WITH TREMFYA^®
SO SIMPLE TRIAL PROGRAM

The TREMFYA^® So Simple Trial Program provides patients their first dose of TREMFYA^® so they may determine with their provider if it is right for them.

FORM for easy enrollment

COST to patient

Shipment can be authorized within 3 BUSINESS DAYS
after prescription.^*

This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends. This program is for medication only. Terms expire at the end of each calendar year and may change.

^*Shipment can be authorized within 3 business days of submitting a prescription, pending patient program opt-in and scheduling shipment.

SUBMIT A COMPLETED PRESCRIPTION ENROLLMENT FORM
(VIA JANSSEN CAREPATH)

FOR COMMERCIALLY INSURED PATIENTS

STAY ON TREMFYA^®

SUBMIT A COMPLETED PRIOR AUTHORIZATION FORM
to the patient's insurance company (via Janssen CarePath or the insurance company directly)

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay

per injection

with a $20,000 maximum program beneﬁt per calendar year

See full program requirements at Tremfya.JanssenCarePathSavings.com.

Patients will receive TREMFYA^® at no cost until they receive insurance coverage approval

See full program requirements at JanssenCarePath.com/Tremfya/Janssen-Link.

Both programs are unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration.

These programs are for medication only. Terms expire at the end of each program year and may change.

JANSSEN CAREPATH

can provide information about other resources that may be able to help your patients with their out-of-pocket costs

Visit JanssenCarePath.com/patient/Tremfya for more information about affordability programs that may be available.

For more information about Janssen CarePath, talk with your Janssen Representative

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728),
Monday-Friday, 8:00 AM to 8:00 PM ET.
Sign Up or Log In to the Provider Portal at JanssenCarePathPortal.com
Visit JanssenCarePath.com

ONE DESTINATION FOR TREMFYA^® ACCESS RESOURCES

Tools and resources to help you support patients to start and stay on TREMFYA^®.

VISIT NOW

JANSSEN CAREPATH IS YOUR ONE SOURCE FOR ACCESS, AFFORDABILITY, AND TREATMENT SUPPORT FOR YOUR PATIENTS

Access support

to help navigate payer processes

Janssen CarePath helps verify insurance coverage for your patients taking TREMFYA^® and provides reimbursement information.

Online Benefits Investigation and Prior Authorization Support

Affordability support

to help your patients start and stay on the treatment you prescribe

Janssen CarePath can help you find out what affordability assistance may be available for your patients taking TREMFYA^®.

Comprehensive Provider Portal to enroll eligible patients in the Janssen CarePath Savings Program and more

Express Enrollment Site for Savings Program for TREMFYA^®

Treatment support

to help your patients get informed and stay on TREMFYA®

Janssen CarePath provides additional support to your patients, including patient education, web-based resources, and personalized reminders.

Learn More

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday to Friday,
8:00 AM to 8:00 PM ET. Multilingual phone support available.

VISIT JanssenCarePath.com

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

After considering the efficacy and safety of TREMFYA^® for your commercially insured adult patients with active psoriatic arthritis (PsA)

CHOOSE TREMFYA^®,
GET TREMFYA^®

START WITH TREMFYA^®
SO SIMPLE TRIAL PROGRAM